Therapeutic Goods Regulations 2022 (TAS)

The Therapeutic Goods Regulations 2022 (TAS) were made under the Therapeutic Goods Act 2001 by the Governor of Tasmania. These regulations, which came into effect on 1 August 2022, mandate compliance with the Code of Good Wholesaling Practice for Medicines in Schedules 2, 3, 4 and 8 and establish labelling standards for certain therapeutic substances. The regulations apply to wholesalers and suppliers of therapeutic goods, particularly those listed in Schedule 8 of the Therapeutic Goods Regulations 1990 of the Commonwealth. The primary focus of the regulations is to ensure that unscheduled therapeutic substances are labelled appropriately to prevent misuse and to ensure safe use.

The key legal issues before the court were whether the regulations were within the legislative authority of the Tasmanian government and whether they complied with the Therapeutic Goods Act 1989 of the Commonwealth. The court had to determine if the regulations were consistent with the overarching federal legislation and if they provided sufficient clarity and enforceability. Additionally, the court examined whether the labelling requirements were reasonable and necessary to achieve the intended public health objectives.

The court found that the Therapeutic Goods Regulations 2022 (TAS) were within the legislative power of the Tasmanian government, as they did not conflict with the federal Therapeutic Goods Act 1989. The court held that the regulations were necessary to ensure the safe and proper use of therapeutic substances by imposing clear labelling standards. The labelling requirements were deemed reasonable and proportionate to the risks associated with unscheduled therapeutic substances. The court also noted that the penalties provided for non-compliance were sufficient to enforce the regulations effectively.

The final orders of the court upheld the validity of the Therapeutic Goods Regulations 2022 (TAS), confirming their compliance with both state and federal legislative frameworks. The court emphasised the importance of clear and consistent labelling to protect public health and ensure the safe use of therapeutic substances.